Scarica l'app Stockscreener
1.525
6.99%
0.095
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Editas Medicine To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Editas Medicine CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 5.4% - MarketBeat
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
State Street Corp Cuts Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Brokerages - MarketBeat
Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share : €-1.69 (As of Sep. 2024) - GuruFocus.com
Editas Medicine stock plunges to 52-week low of $1.27 - Investing.com
Cambridge company is laying of 180 people, 65% of its workforce - MSN
Editas Medicine's SWOT analysis: gene editing firm pivots strategy amid stock uncertainty - Investing.com
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program - MSN
JP Morgan Downgrades Editas Medicine (EDIT) - MSN
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce - MSN
EDIT Stock Falls On Decision To End Reni-Cel Studies, Cut Workforce - Barchart
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Evercore ISI - MarketBeat
JPMorgan Chase & Co. Downgrades Editas Medicine (NASDAQ:EDIT) to Underweight - MarketBeat
Five things: Editas cuts, CVS shares, Moderna's name and the best birthday gift ever - The Business Journals
Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% - MSN
Editas cut to equal weight by Wells Fargo over reni-cel positioning - MSN
Chardan Capital Downgrades Editas Medicine (EDIT) - MSN
Barclays Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00 - MarketBeat
Editas Medicine price target lowered to $8 from $10 at Baird - Yahoo Finance
Editas Medicine to reduce about 65% of its workforce over the next six months - ETHRWorld.com
Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts - GuruFocus.com
Truist cuts Editas Medicine stock to Hold, removes price target By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $4.00 at Royal Bank of Canada - MarketBeat
Editas Medicine (EDIT) PT Lowered to $5 at Evercore ISI - StreetInsider.com
Cambridge biotech company lays off more than half its employees - NBC Boston
Gene-editing pioneer Editas lays off more than half its employees - The Business Journals
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program (NASDAQ:EDIT) - Seeking Alpha
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Editas Medicine's (EDIT) "Neutral" Rating Reaffirmed at Chardan Capital - MarketBeat
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $8.00 by Analysts at Robert W. Baird - MarketBeat
Editas to lay off staff after search for sickle cell partner comes up empty - Yahoo Finance
Editas Medicine (NASDAQ:EDIT) Downgraded to Hold Rating by Truist Financial - MarketBeat
Chardan Capital Markets Downgrades Editas Medicine (EDIT) to Neutral - StreetInsider.com
Editas Medicine (NASDAQ:EDIT) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner - BioSpace
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Benzinga
Editas axes two-thirds of its staff, including its CMO - pharmaphorum
Editas Medicine stock plunges to 52-week low at $1.89 By Investing.com - Investing.com Canada
Editas stock downgraded to hold, price target slashed - Investing.com
Editas Medicine's SWOT analysis: gene editing firm's stock faces pivotal phase - Investing.com Nigeria
Editas Medicine, Inc. Announces Management Changes - Marketscreener.com
Editas shifts focus to in vivo CRISPR gene editing - Investing.com India
Editas to reduce about 65% of its workforce over the next six months - 1470 & 100.3 WMBD
Editas Medicine Announces Strategic Transition to in vivo - GlobeNewswire
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years - The Manila Times
Editas Medicine Pivots Gene Editing Strategy, Cutting 65% of Workforce - MarketWatch
3.44%
2.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):